On November 10, 2023, Cybin Inc., a leading biotech company specializing in clinical-stage psychedelics, announced the launch of a unique underwritten offering. This offering consists of 66.66 million units and is available to both its largest institutional shareholder and new institutional investors. The unit price has been set at $0.45, and the offering is scheduled to close
On November 10, 2023, Cybin Inc., a leading biotech company specializing in clinical-stage psychedelics, announced the launch of a unique underwritten offering. This offering consists of 66.66 million units and is available to both its largest institutional shareholder and new institutional investors. The unit price has been set at $0.45, and the offering is scheduled to close […]
Cannabis Law Report